More articles about Point-of-Care Testing

Researchers at Washington University in Saint Louis will use new funds to confirm preliminary findings on malaria-infected kids in a second location in Africa.

A molecular assay used in combination with patient-collected samples had similar accuracy to testing with clinician collected samples. 

The funds will help commercialize Ador's NATlab reader, a point-of-care MDX platform for sample-to-answer identification of specific infectious diseases.

The kit is for quantitatively measuring the percent of glycated hemoglobin, total cholesterol, high-density lipoprotein, triglycerides, and glucose.

The firm hopes to seek 510(k) clearance from the US Food and Drug Administration for its combined identification and antimicrobial sensitivity test by the end of 2019.

The diagnostic test, IBS-smart, which measures antibodies that are elevated in patients with post-infectious irritable bowel syndrome, is already available to physicians in the US.

The immunoassay is designed to detect syphilis treponemal antibodies in primary and secondary syphilis from a single drop of fingerstick blood.

Alere rapid diagnostics revenues were $548 million in the quarter, driven by infectious disease and cardiometabolic testing product sales.

Galaxy has licensed IP from Proteome Sciences for the development of a test for the diagnosis and timing of stroke onset to help inform treatment decisions.

The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.

Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time. 

Its most advanced gene expression signatures are for infectious disease diagnostics and are aimed at enabling the appropriate prescription of antiviral and antibiotic medications.

The financing will go toward continued development of its MultiPath technology to rapidly identify hospital infections and determine their antibiotic susceptibility.

AllerGenis has the non-exclusive right to use the xMAP technology to develop, market, and sell a precision food allergy diagnostic assay.

The company will provide 1 million rapid diagnostic tests, $750,000, and technical expertise as part of an effort in Odisha to eliminate the disease.

Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.


eTrueNorth and Southeastern Grocers are partnering to launch the labs. Southeastern's grocery stores will also participate in eTrueNorth's biometric data program.

The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.

Worcester Polytechnic Institute researchers are developing an inexpensive handheld platform that could provide C. difficile test results in minutes.

A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.

Pages